<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718844</url>
  </required_header>
  <id_info>
    <org_study_id>SLN124-002</org_study_id>
    <nct_id>NCT04718844</nct_id>
  </id_info>
  <brief_title>A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Randomised, Single-blind, Placebo-controlled, Phase 1, Single-ascending and Multiple-dose Study in Adult Subjects With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silence Therapeutics plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silence Therapeutics plc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety and tolerability of SLN124 in patients with&#xD;
      Thalassaemia or patients with Very Low- and Low-risk Myelodysplastic Syndrome after single&#xD;
      ascending s.c. doses and multiple doses in healthy male and female subjects. Up to 7 cohorts&#xD;
      of 56 patients with Thalassaemia and up to 7 cohorts of 56 patients with Myelodysplastic&#xD;
      Syndrome will be enrolled. Each subject will receive single or multiple doses of SLN124 or&#xD;
      placebo given by subcutaneous (s.c) injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Day 84</time_frame>
    <description>safety and tolerability will be reported separately following single-dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Day 140</time_frame>
    <description>safety and tolerability will be reported separately following multi-dose administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: peak plasma concentration (Cmax)</measure>
    <time_frame>Day 84 and Day 140</time_frame>
    <description>Will be reported separately following single-dose and multiple-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: area under the plasma concentration (AUC)</measure>
    <time_frame>Day 84 and Day 140</time_frame>
    <description>Will be reported separately following single-dose and multiple-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: apparent total clearance from plasma after s.c injection (CL/F)</measure>
    <time_frame>Day 84 and Day 140</time_frame>
    <description>Will be reported separately following single-dose and multiple-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic biomarkers: Change in TSAT after s.c injection.</measure>
    <time_frame>Day 84 and Day 140</time_frame>
    <description>safety and tolerability will be reported separately following single-dose and multiple-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic biomarkers: Change in hepcidin after s.c injection.</measure>
    <time_frame>Day 84 and Day 140</time_frame>
    <description>safety and tolerability will be reported separately following single-dose and multiple-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic biomarkers: Change in serum iron after s.c injection.</measure>
    <time_frame>Day 84 and Day 140</time_frame>
    <description>safety and tolerability will be reported separately following single-dose and multiple-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic biomarkers: Change in haemoglobin after s.c injection.</measure>
    <time_frame>Day 84 and Day 140</time_frame>
    <description>safety and tolerability will be reported separately following single-dose and multiple-dose administration.</description>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Non-transfusion-dependent Thalassemia</condition>
  <condition>Low Risk Myelodysplastic Syndrome</condition>
  <condition>Very-Low Risk Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>1.0mg/kg - Thalassaemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0mg/kg - Thalassaemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10.0mg/kg - Thalassaemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Thalassaemia</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xmg/kg - Thalassaemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0mg/kg - Myelodysplastic Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0mg/kg - Myelodysplastic Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10.0mg/kg - Myelodysplastic Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xmg/kg - Myelodysplastic Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0mg/kg - Thalassaemia multi dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10.0mg/kg - Thalassaemia multi dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xmg/kg - Thalassaemia multi dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0mg/kg - Myelodysplastic Syndrome multi dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10.0mg/kg - Myelodysplastic Syndrome multi dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xmg/kg - Myelodysplastic Syndrome multi dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Thalassaemia multi dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Myelodysplastic Syndrome</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Myelodysplastic Syndrome multi dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLN124</intervention_name>
    <description>SLN124 for subcutaneous (s.c.) injection</description>
    <arm_group_label>1.0mg/kg - Myelodysplastic Syndrome</arm_group_label>
    <arm_group_label>1.0mg/kg - Thalassaemia</arm_group_label>
    <arm_group_label>10.0mg/kg - Myelodysplastic Syndrome</arm_group_label>
    <arm_group_label>10.0mg/kg - Myelodysplastic Syndrome multi dose</arm_group_label>
    <arm_group_label>10.0mg/kg - Thalassaemia</arm_group_label>
    <arm_group_label>10.0mg/kg - Thalassaemia multi dose</arm_group_label>
    <arm_group_label>3.0mg/kg - Myelodysplastic Syndrome</arm_group_label>
    <arm_group_label>3.0mg/kg - Myelodysplastic Syndrome multi dose</arm_group_label>
    <arm_group_label>3.0mg/kg - Thalassaemia</arm_group_label>
    <arm_group_label>3.0mg/kg - Thalassaemia multi dose</arm_group_label>
    <arm_group_label>Xmg/kg - Myelodysplastic Syndrome</arm_group_label>
    <arm_group_label>Xmg/kg - Myelodysplastic Syndrome multi dose</arm_group_label>
    <arm_group_label>Xmg/kg - Thalassaemia</arm_group_label>
    <arm_group_label>Xmg/kg - Thalassaemia multi dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium chloride for s.c. injection</description>
    <arm_group_label>Placebo - Myelodysplastic Syndrome</arm_group_label>
    <arm_group_label>Placebo - Myelodysplastic Syndrome multi dose</arm_group_label>
    <arm_group_label>Placebo - Thalassaemia</arm_group_label>
    <arm_group_label>Placebo - Thalassaemia multi dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult with alpha- or beta-thalassaemia or compound heterozygous haemoglobin&#xD;
             E/beta-thalassaemia or adult with very low- or low-risk MDS according to the 2016&#xD;
             revision to the World Health Organisation classification.&#xD;
&#xD;
          -  All subjects must agree to adhere to appropriate contraception requirements.&#xD;
&#xD;
          -  Subjects must provide written informed consent and be able to comply with all study&#xD;
             requirements.&#xD;
&#xD;
          -  Body mass index ≥18 kg/m2 and ≤35 kg/m2 at screening.&#xD;
&#xD;
          -  At least one of: a) Mean ferritin &gt;250 μg/L based on a minimum of 2 measurements ≥1&#xD;
             week apart within 20 days before the planned dosing day, in the absence of active&#xD;
             significant infection; b) Mean TSAT &gt;40% measured on a minimum of 2 occasions ≥1 week&#xD;
             apart within 20 days before the planned dosing day; c) Liver iron &gt;3 mg Fe/g dry&#xD;
             weight, measured according to local procedures.&#xD;
&#xD;
          -  Mean baseline haemoglobin concentration ≥5 g/dL and ≤11 g/dL, based on a minimum of 2&#xD;
             measurements ≥1 week apart, within 20 days before the planned dosing day.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Adult with haemoglobin S/alpha-thalassaemia or haemoglobin S/beta-thalassaemia or&#xD;
             adult with secondary MDS, i.e., MDS that is known to have arisen because of chemical&#xD;
             injury or treatment with chemotherapy and/or radiation for another disease.&#xD;
&#xD;
          -  History of multiple drug allergies or history of allergic reaction to an&#xD;
             oligonucleotide or GalNAc, or intolerance to s.c. injections.&#xD;
&#xD;
          -  Known infection with HIV, or active infectious hepatitis A, B, or C virus.&#xD;
&#xD;
          -  Any conditions which, in the opinion of the Investigator, would make the subject&#xD;
             unsuitable for enrolment in the study or could interfere with the subject's&#xD;
             participation in, or completion of the study.&#xD;
&#xD;
          -  History or clinical evidence of alcohol or illegal drug misuse within 2 years before&#xD;
             screening.&#xD;
&#xD;
          -  Currently using ESA, or plan to use ESA at any point during the study.&#xD;
&#xD;
          -  Require daily treatment with 1 or more non-steroidal anti-inflammatory drugs during&#xD;
             the study period. Paracetamol will be permitted for use as an antipyretic and/or&#xD;
             analgesic.&#xD;
&#xD;
          -  Treatment, or change in treatment with prohibited medications as specified in the&#xD;
             protocol&#xD;
&#xD;
          -  Treatment with ICT where the subject has not been on a stable dose for at least 8&#xD;
             weeks before screening or it is planned to initiate ICT therapy during the study.&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Clinically significant pulmonary disease&#xD;
&#xD;
        For subjects with thalassaemia:&#xD;
&#xD;
          -  Treatment, or change in treatment with prohibited medications as specified in the&#xD;
             protocol&#xD;
&#xD;
          -  currently and anticipated to receiving more than 5 units of RBCs during the 24 weeks&#xD;
             to 6 weeks period before first dose of study drug.&#xD;
&#xD;
        For subjects with very low / low-risk MDS:&#xD;
&#xD;
          -  Previous allogeneic or autologous stem cell transplantation.&#xD;
&#xD;
          -  Currently or planned to receive treatment with a corticosteroid for MDS within 8 weeks&#xD;
             before screening.&#xD;
&#xD;
          -  Currently or planned to receive treatment with haematopoietic growth factors (e.g.,&#xD;
             eltrombopag, romiplostim) within 8 weeks before screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristin Greenough</last_name>
    <phone>+44 20 3934 8038</phone>
    <email>k.greenough@silence-therapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena Townson</last_name>
    <phone>+44 20 3934 8038</phone>
    <email>e.townson@silence-therapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Amal El Beshlawy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Duesseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Norbert Gattermann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitat Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Uwe Platzbecker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Avraham Frisch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Drorit Merkel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Moshe Mittelman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bar-Ilan University - Faculty of Medicine</name>
      <address>
        <city>Zefat</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Najib Dally</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AUSL della Romagna - Ospedale di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michela Rondoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Isabella Capodanno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jordan University Hospital</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Abddullah Awidi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Hussein Cancer Center</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Waleed Da'Na</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nini Hopital</name>
      <address>
        <city>Tripoli</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Kampung Sarawak</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ampang</name>
      <address>
        <city>Kampung Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mahidol University - Faculty of Medicine - Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mahidol University - Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Leeds Teaching Hospitals NHS Trust - Saint James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

